Meta's Prescription Glasses: A $70B Market Cap Pop on a Niche Launch

Meta launched two new prescription Ray-Ban smart glasses on Tuesday, expanding its niche in AI-powered wearables. The new models, available for pre-order in the U.S. starting at $499, are set to hit optical retailers on April 14. This move follows the company's earlier Display model, which faced a delayed global rollout due to supply constraints.

The immediate market reaction was a sharp pop. Shares jumped nearly 4% in morning trading, with one report noting the stock surged over 5% and recovered more than $70 billion in market cap. This rebound is significant given the stock's recent weakness, having fallen around 19% so far this year. The price action suggests the move is driven more by dip-buying and short-term catalysts than by new fundamental conviction in the product's scale.

The launch coincided with other positive signals, including a Morgan Stanley upgrade and renewed investor confidence in Meta's AI infrastructure spending. Yet the sheer magnitude of the market cap recovery-over $70 billion-on a product launch in a specific eyewear segment highlights the volatility and sensitivity of the stock to any perceived growth catalyst, especially after a steep year-to-date decline.

Assessing the Product's Financial Scale

The smart glasses segment is a clear breakout success. Global shipments hit 9.6 million units last year, with Meta capturing a dominant 76.1% of the total. That volume represents a tripling of prior-year sales, establishing the category's rapid growth.

The new prescription models are priced to target this massive demographic. They are available for pre-order in the U.S. starting at $499, a premium segment aimed at the billions of people who wear glasses or contacts for vision correction.

Yet, even this success remains a tiny fraction of Meta's overall business. The new product line operates within a context where the company's total revenue for the last quarter was $59.9 billion. The scale of the smart glasses market, while impressive, is still a niche play within a colossal, ad-driven empire.

The AI Investment Thesis and Valuation Context

Meta's core investment thesis is anchored in massive, accelerating capital expenditure. The company plans to spend $115-$135 billion on AI infrastructure in 2026, a significant increase from $69.7 billion in 2025. This scale of spending underscores the strategic priority of building the underlying hardware and software for its "personal superintelligence" vision, a push that includes the prescription glasses as a niche product.

The stock's current valuation reflects a discount to this growth trajectory. It trades at 15x projected 2027 earnings, a multiple that analysts see as a gap to the broader consensus. The $846.63 consensus price target implies substantial upside, suggesting the market is pricing in the long-term payoff of these investments rather than near-term product launches.

Viewed through this lens, the prescription glasses launch is a small part of a much larger bet. While the product is a success within its segment, the stock's recent pop is driven more by renewed confidence in the AI infrastructure spending thesis and a Morgan Stanley upgrade. The glasses represent a tangible step toward the "personal superintelligence" future, but the valuation is being set by the scale of the underlying capital commitment.